Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Holdings
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Director departure
Appointed director
Acer Therapeutics Inc. (ACER) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/14/2023 8-K Quarterly results
Docs: "Acer Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update OLPRUVA™ kits now available in all dosage strengths and ready to ship to patients NEWTON, MA – August 14, 2023 – Acer Therapeutics Inc. , a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and life-threatening diseases with significant unmet medical needs, today reported financial results for the second quarter ended June 30, 2023 and provided a corporate update. “The second quarter of 2023 marked continued progress for Acer as we execute on our OLPRUVA™ launch strategy,” said Chris Schelling, CEO and Founder of Acer. “We are pleased to offer OLPRUVA™ in the U.S. to certain UCD patients as a novel alternative o..."
05/15/2023 8-K Quarterly results
Docs: "Acer Therapeutics Reports Q1 2023 Financial Results and Provides Corporate Update U.S. OLPRUVA™ launch progressing ahead of schedule with drug-in-channel now anticipated in mid-June 2023 NEWTON, MA – May 15, 2023 – Acer Therapeutics Inc. , a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and life-threatening diseases with significant unmet medical needs, today reported financial results for the first quarter ended March 31, 2023 and provided a corporate update. “The first quarter of 2023 was marked by considerable progress and a number of significant milestones in support of our commercial launch of OLPRUVA™, an innovative treatment option for patients with certain Urea Cycle Disorders ,” said Chris Schellin..."
11/14/2022 8-K Quarterly results
08/15/2022 8-K Quarterly results
05/16/2022 8-K Quarterly results
03/02/2022 8-K Quarterly results
11/19/2021 8-K Quarterly results
Docs: "Acer Therapeutics Reports Q3 2021 Financial Results and Provides Corporate Update"
05/17/2021 8-K Quarterly results
03/01/2021 8-K Quarterly results
11/10/2020 8-K Investor presentation, Quarterly results
Docs: "Acer Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update",
"Acer Therapeutics Inc. Corporate Presentation, November 2020"
08/13/2020 8-K Quarterly results
05/14/2020 8-K Quarterly results
03/18/2020 8-K Investor presentation, Quarterly results
Docs: "Pillsbury Winthrop Shaw Pittman LLP",
"Acer Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update OND denies Acer’s appeal but describes possible paths forward for EDSIVO&#8482",
"Acer Therapeutics Inc. Corporate Presentation, March 2020",
"Acer Receives Formal Dispute Resolution Request Response from FDA’s Office of New Drugs Office of New Drugs denies Acer’s appeal but describes possible paths forward for EDSIVO&#8482"
11/13/2019 8-K Quarterly results
08/13/2019 8-K Investor presentation, Quarterly results
Docs: "Acer Therapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Update",
"Acer Therapeutics Inc. Investor Presentation, August 2019"
05/14/2019 8-K Quarterly results
Docs: "Acer Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update Acer executing on pre-commercial launch plan for EDSIVO™ while growing and advancing its pipeline"
11/09/2018 8-K Quarterly results
Docs: "Acer Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update Acer continues to progress towards goal of commercializing EDSIVO™ Company appoints VPs of Corporate Development and IT & Database Administrator"
08/13/2018 8-K Quarterly results
Docs: "Acer Therapeutics Reports Second Quarter 2018 Financial Results and Provides Corporate Update Acer continues to progress towards goal of commercializing EDSIVO™ Company appoints VPs of Medical Affairs and Quality"
05/14/2018 8-K Quarterly results
Docs: "Acer Therapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update Acer continues progression from development to potential commercialization of EDSIVO&#8482"
11/13/2017 8-K Quarterly results
Docs: "Acer Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate Update Closed Merger and Concurrent $15.7M Financing Announced Positive Results from Pivotal Clinical Trial of EDSIVO™ for Treatment of vEDS CAMBRIDGE, MA – Nov. 13, 2017 – Acer Therapeutics Inc. , a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and ultra-rare diseases with critical unmet medical need, today reported financial results for the quarter ended September 30, 2017 and provided an update on the Company’s recent corporate developments. “The third quarter was transformative for Acer. We became a public Nasdaq-listed company, closed a concurrent financing and announced positive results from our pivotal clinical trial..."
08/14/2017 8-K Quarterly results
Docs: "Opexa Therapeutics Reports Second Quarter 2017 Financial Results and Provides Corporate Update"
05/12/2017 8-K Form 8-K - Current report
11/14/2016 8-K Quarterly results
Docs: "Opexa Therapeutics Reports Third Quarter 2016 Financial Results and Provides Corporate Update"
08/11/2016 8-K Quarterly results
Docs: "Opexa Therapeutics Reports Second Quarter 2016 Financial Results and Provides Corporate Update Abili-T Trial in Secondary Progressive MS On-Schedule With Top-line Results Expected in Early Q4"
05/12/2016 8-K Quarterly results
Docs: "Opexa Therapeutics Reports First Quarter 2016 Financial Results and Provides Corporate Update Conference Call Scheduled Today at 4:30 PM ET"
11/10/2015 8-K Quarterly results
Docs: "Opexa Therapeutics Reports Third Quarter 2015 Financial Results and Provides Corporate Update",
"Opexa Therapeutics, Inc. slide presentation for Analyst and Investor Event on November 10, 2015",
"Opexa Therapeutics Announces Supportive Preclinical Study Results for its Neuromyelitis Optica Program"
08/12/2015 8-K Quarterly results
Docs: "Opexa Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update"
05/12/2015 8-K Quarterly results
Docs: "Opexa Therapeutics Reports First Quarter 2015 Financial Results and Provides Corporate Update",
"Opexa Therapeutics, Inc. Investor Presentation, May 2015"
11/06/2014 8-K Quarterly results
Docs: "Opexa Therapeutics Reports Third Quarter 2014 Financial Results and Provides Corporate Update"
08/14/2014 8-K Quarterly results
Docs: "Opexa Therapeutics Reports Second Quarter 2014 Financial Results and Provides Corporate Update",
"Opexa Therapeutics, Inc. Investor Presentation, August 2014"
05/14/2014 8-K Investor presentation, Quarterly results
Docs: "Opexa Therapeutics Reports First Quarter 2014 Financial Results and Provides Corporate Update",
"Opexa Therapeutics, Inc. Earnings Update Teleconference Presentation"
11/07/2013 8-K Form 8-K - Current report
08/14/2013 8-K Form 8-K - Current report
05/14/2013 8-K Investor presentation, Quarterly results
Docs: "Opexa Therapeutics Reports First Quarter 2013 Financial Results and Provides Corporate Update",
"Opexa Therapeutics, Inc. Earnings Update Teleconference Presentation"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy